FDA Grants Accelerated Approval Of Avastin In Combination With Paclitaxel Chemotherapy For Treatment Of Advanced HER2-Negative Breast Cancer

Genentech, Inc. (NYSE:DNA) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Avastin® (bevacizumab), in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer.

More: continued here

Filed under: Breast Cancer on February 26th, 2008